Raymond James analyst John Ransom upgraded UnitedHealth to Strong Buy from Outperform with a price target of $630, up from $615. Following the stock’s underperformance year-to-date, the analyst is more constructive on the shares. The setup going forward is more favorable as many of the policy overhangs are behind the company and UnitedHealth is well positioned to have a strong 2023, the analyst tells investors in a research note. The firm remains convinced that legislative risks are minimal.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UNH:
- 3 Best Stocks to Buy Now, 4/5/2023, According to Top Analysts
- UnitedHealth to reduce use of prior authorization process, Reuters reports
- RBC upgrades Elevance Health on building Carelon momentum
- ‘The End of the Bear Market May Be in Sight,’ Says Morgan Stanley. Here Are 3 Stocks the Banking Giant Likes for Long-Term Growth
- Humana stock a bet on healthcare for seniors, Barron’s says
